Loading…
Employees: 1,155
Size PharmaResources (Shanghai) (301230.SZ) is a China Industrials company (Miscellaneous Commercial Services) with a market value of $822M, the 2691st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥30.63 on 6 Nov 2026.
Performance Over six months the shares fell 3.8%, against -1.3% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +5.2%); the operating margin is 0.3% (peer median 9.7%).
Valuation It trades at 90.5× forward earnings against a peer median of 19.9× (most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +20%, so the hurdle is +23 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 4.9 points below its cost of capital (11.2% WACC).
Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥724M | CN¥688M | CN¥543M | CN¥488M | CN¥477M |
| Revenue growth | — | +27% | +11% | +2% | — |
| Gross profit | CN¥233M | CN¥146M | CN¥99.1M | CN¥138M | CN¥166M |
| EBITDA | n/a | CN¥118M | CN¥69.2M | CN¥76.6M | CN¥97.8M |
| Net income | CN¥28.6M | CN¥34.3M | CN¥17.1M | CN¥37.6M | CN¥67.2M |
| Free cash flow | CN¥94.1M | CN¥92.3M | -CN¥25.1M | -CN¥221M | -CN¥116M |
| Capital expenditure | CN¥79.0M | CN¥43.3M | CN¥109M | CN¥248M | CN¥124M |
| Total debt | CN¥144M | CN¥167M | CN¥188M | CN¥215M | CN¥111M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 301230.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.7% | -4.3% | 6th lowest of 21 |
| 6-month return | -3.8% | -1.3% | 11th highest of 21 |
| Distance from 52-week high | -41.4% | -30.2% | 8th lowest of 21 |
| Revenue growth (TTM) | +8.9% | +5.2% | 8th highest of 21 |
| Operating margin | 0.3% | 9.7% | 5th lowest of 21 |
| Forward P/E | 90.5× | 19.9× | most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 42.7% | 7.5% | most demanding of 13 |
| Growth delivered (Del g) | +19.5% | +17.6% | 5th highest of 13 |
| Hurdle (Req g minus delivered) | +23.2 pp | -18.2 pp | 2nd most demanding of 13 |
| ROIC minus cost of capital | -4.9 pp | -0.0 pp | 6th lowest of 19 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| PharmaResources (Shanghai) 301230.SZ | China | $822M | -4% | +9% | 0% | 90.5× | 42.7% | +19.5% |
| Cuscal CCL.AX | Australia | $815M | +26% | +19% | 12% | 19.6× | n/a | n/a |
| Karnov KAR.ST | Sweden | $828M | +16% | -4% | 20% | 20.2× | 4.1% | +27.9% |
| Anbang Save-Guard 603373.SS | China | $830M | +30% | -1% | 14% | 41.5× | 6.7% | +5.6% |
| Beyondsoft 002649.SZ | China | $813M | -12% | -6% | 2% | 25.5× | 8.3% | +9.2% |
| TaskUs TASK | United States | $833M | +41% | +11% | 12% | 6.5× | 0.5% | +19.9% |
| Omat Advanced Materials (Guangdong) 688530.SS | China | $809M | -16% | +82% | 9% | n/a | n/a | n/a |
| transcosmos 9715.T | Japan | $802M | -12% | +6% | 4% | 9.6× | -18.5% | +3.2% |
| AXISCADES Technologies AXISCADES.NS | India | $802M | -17% | +5% | 10% | 7.8× | n/a | n/a |
| Huatu Cendes 300492.SZ | China | $800M | -44% | -8% | -2% | n/a | 17.6% | +91.2% |
| Funshine Culture 300860.SZ | China | $858M | +21% | -49% | -35% | 28.1× | 27.8% | -24.6% |
| Shaanxi Lighte Optoelectronics Material 688150.SS | China | $787M | -44% | +14% | 39% | 40.0× | n/a | n/a |
| NOMURA 9716.T | Japan | $861M | +4% | -10% | 7% | 14.1× | -8.4% | +8.6% |
| DOOSAN TESNA 131970.KS | South Korea | $861M | -53% | +3% | 11% | 36.9× | 17.8% | +18.1% |
| Damon Technology 688360.SS | China | $779M | +8% | +19% | 7% | 7.2× | 12.3% | +17.1% |
| Shandong Link Science and Technology 001207.SZ | China | $777M | -7% | +7% | 13% | 12.3× | -4.6% | +18.9% |
| Daqian Ecology & Environment 603955.SS | China | $776M | +21% | +217% | -53% | n/a | n/a | n/a |
| Aimed Bio 0009K0.KS | South Korea | $875M | -61% | +223% | 36% | n/a | 13.2% | +652.2% |
| Dark Horse Technology 300688.SZ | China | $770M | +18% | -32% | -33% | 57.9× | n/a | n/a |
| IP Group plc IPO.L | United Kingdom | $879M | +13% | -37% | 51% | 11.9× | n/a | n/a |
| Zhejiang Zhongxin Fluoride Materials 002915.SZ | China | $767M | -17% | +8% | 2% | 66.3× | n/a | n/a |